ArticleRadiology2020
CD38-targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human Imaging.
Open access · greenAbstract readClinical Trial, Phase I
In one paragraph
Article in Radiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
72citing papers in PubMed, 1 pooled it
10.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 1 synthesis or guideline pooled it, 119 citations in OpenAlex.
- EANM guidelines on the use of [European journal of nuclear medicine and molecular imaging · 2024Guideline
- Review
- CD70-targeted platform for diagnosing and treating multiple myeloma.Journal for immunotherapy of cancer · 2026Article
- Smoldering multiple myeloma in transition: redefining early myeloma in the modern era.Leukemia · 2026Review
- Clinical nuclear medicine applications of zirconium-89 immuno-PET: a comprehensive review from a radiopharmaceutical perspective.EJNMMI radiopharmacy and chemistry · 2026Review
- PET Imaging of CD38 and IND enabling studies of [Molecular imaging and biology · 2026Article
- Emerging ImmunoPET probes for precision cancer immunotherapy: molecular targets and translational applications.Frontiers in oncology · 2026Review
- Advancements in Targeted Radiopharmaceuticals: Innovations in Diagnosis and Therapy for Enhanced Cancer Management.Chembiochem : a European journal of chemical biology · 2026Review
- Immuno-positron emission tomography as a new frontier in imaging hematologic malignancies.World journal of clinical oncology · 2025Review
- Refractory Multiple Myeloma in a West Highland White Terrier: Clinical Presentations and Therapeutic Interventions.Animals : an open access journal from MDPI · 2025Article
- Advanced quantification pipeline reveals new spatial and temporal tumor characteristics in preclinical multiple myeloma.EJNMMI research · 2025Article
- CD38-specific immunoPET imaging for multiple myeloma diagnosis and therapeutic monitoring: preclinical and first-in-human studies.European journal of nuclear medicine and molecular imaging · 2025Article
- Diagnostic Innovations: Advances in imaging techniques for diagnosis and follow-up of multiple myeloma.Journal of bone oncology · 2025Review
- A minimal physiologically-based pharmacokinetic modeling platform to predict intratumor exposure and receptor occupancy of an anti-LAG-3 monoclonal antibody.CPT: pharmacometrics & systems pharmacology · 2025Article
- Minimal Residual Disease Significance in Multiple Myeloma Patients Treated with Anti-CD38 Monoclonal Antibodies.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Radiopharmaceuticals and their applications in medicine.Signal transduction and targeted therapy · 2025Review
- Emerging Imaging Techniques for Atherosclerosis in Systemic Immune-Mediated Inflammatory Conditions.Arteriosclerosis, thrombosis, and vascular biology · 2025Review
- Non-[Pharmaceuticals (Basel, Switzerland) · 2024Review
- CD38 as theranostic target in oncology.Journal of translational medicine · 2024Review
- Development of New CD38 Targeted Peptides for Cancer Imaging.Molecular imaging and biology · 2024Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
11 authors at 1 institution in 1 country.
Gary A Ulaner *From the Department of Radiology (G.A.U., N.B.S., C.C.R., R.M., L.M.C., S.K.L., J.S.L.), Department of Medical Physics (J.A.O., A.S.K.), Myeloma Service, Department of Medicine (E.S., C.O.L.), and Molecular Pharmacology Program (J.S.L.), Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065; and Department of Radiology, Weill Cornell Medical College, New York, NY (G.A.U., C.C.R., J.S.L.).ORCID 0000-0002-7953-0113
Nicholas B Sobol *From the Department of Radiology (G.A.U., N.B.S., C.C.R., R.M., L.M.C., S.K.L., J.S.L.), Department of Medical Physics (J.A.O., A.S.K.), Myeloma Service, Department of Medicine (E.S., C.O.L.), and Molecular Pharmacology Program (J.S.L.), Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065; and Department of Radiology, Weill Cornell Medical College, New York, NY (G.A.U., C.C.R., J.S.L.).
Joseph A O'DonoghueFrom the Department of Radiology (G.A.U., N.B.S., C.C.R., R.M., L.M.C., S.K.L., J.S.L.), Department of Medical Physics (J.A.O., A.S.K.), Myeloma Service, Department of Medicine (E.S., C.O.L.), and Molecular Pharmacology Program (J.S.L.), Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065; and Department of Radiology, Weill Cornell Medical College, New York, NY (G.A.U., C.C.R., J.S.L.).ORCID 0000-0002-2761-0015
Assen S KirovFrom the Department of Radiology (G.A.U., N.B.S., C.C.R., R.M., L.M.C., S.K.L., J.S.L.), Department of Medical Physics (J.A.O., A.S.K.), Myeloma Service, Department of Medicine (E.S., C.O.L.), and Molecular Pharmacology Program (J.S.L.), Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065; and Department of Radiology, Weill Cornell Medical College, New York, NY (G.A.U., C.C.R., J.S.L.).ORCID 0000-0001-6521-3582
Christopher C RiedlFrom the Department of Radiology (G.A.U., N.B.S., C.C.R., R.M., L.M.C., S.K.L., J.S.L.), Department of Medical Physics (J.A.O., A.S.K.), Myeloma Service, Department of Medicine (E.S., C.O.L.), and Molecular Pharmacology Program (J.S.L.), Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065; and Department of Radiology, Weill Cornell Medical College, New York, NY (G.A.U., C.C.R., J.S.L.).ORCID 0000-0002-7859-6997
Ryan MinFrom the Department of Radiology (G.A.U., N.B.S., C.C.R., R.M., L.M.C., S.K.L., J.S.L.), Department of Medical Physics (J.A.O., A.S.K.), Myeloma Service, Department of Medicine (E.S., C.O.L.), and Molecular Pharmacology Program (J.S.L.), Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065; and Department of Radiology, Weill Cornell Medical College, New York, NY (G.A.U., C.C.R., J.S.L.).ORCID 0000-0002-5213-0267
Eric SmithFrom the Department of Radiology (G.A.U., N.B.S., C.C.R., R.M., L.M.C., S.K.L., J.S.L.), Department of Medical Physics (J.A.O., A.S.K.), Myeloma Service, Department of Medicine (E.S., C.O.L.), and Molecular Pharmacology Program (J.S.L.), Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065; and Department of Radiology, Weill Cornell Medical College, New York, NY (G.A.U., C.C.R., J.S.L.).
Lukas M CarterFrom the Department of Radiology (G.A.U., N.B.S., C.C.R., R.M., L.M.C., S.K.L., J.S.L.), Department of Medical Physics (J.A.O., A.S.K.), Myeloma Service, Department of Medicine (E.S., C.O.L.), and Molecular Pharmacology Program (J.S.L.), Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065; and Department of Radiology, Weill Cornell Medical College, New York, NY (G.A.U., C.C.R., J.S.L.).ORCID 0000-0003-4848-4190
Serge K LyashchenkoFrom the Department of Radiology (G.A.U., N.B.S., C.C.R., R.M., L.M.C., S.K.L., J.S.L.), Department of Medical Physics (J.A.O., A.S.K.), Myeloma Service, Department of Medicine (E.S., C.O.L.), and Molecular Pharmacology Program (J.S.L.), Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065; and Department of Radiology, Weill Cornell Medical College, New York, NY (G.A.U., C.C.R., J.S.L.).
Jason S LewisFrom the Department of Radiology (G.A.U., N.B.S., C.C.R., R.M., L.M.C., S.K.L., J.S.L.), Department of Medical Physics (J.A.O., A.S.K.), Myeloma Service, Department of Medicine (E.S., C.O.L.), and Molecular Pharmacology Program (J.S.L.), Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065; and Department of Radiology, Weill Cornell Medical College, New York, NY (G.A.U., C.C.R., J.S.L.).ORCID 0000-0001-7065-4534
C Ola LandgrenFrom the Department of Radiology (G.A.U., N.B.S., C.C.R., R.M., L.M.C., S.K.L., J.S.L.), Department of Medical Physics (J.A.O., A.S.K.), Myeloma Service, Department of Medicine (E.S., C.O.L.), and Molecular Pharmacology Program (J.S.L.), Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065; and Department of Radiology, Weill Cornell Medical College, New York, NY (G.A.U., C.C.R., J.S.L.).ORCID 0000-0001-6485-4839
Memorial Sloan Kettering Cancer Center · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MLeveraging Pb-203/212 for the Theranostic Imaging and Therapy of Prostate CancerR35CA232130 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI LEWIS, JASON S. · 2019 to 2025
$8.2MDevelopment of a Novel Peptide Platform for Targeted PET Imaging and Radiotherapy of Breast CancerF32EB025050 · NIBIB · SLOAN-KETTERING INST CAN RESEARCH · PI CARTER, LUKAS MICHAEL · 2017 to 2019
$179kNCI NIH HHS P30 CA008748NCI NIH HHS R35 CA232130NIBIB NIH HHS F32 EB025050
Abstract
Background Current measurements of multiple myeloma disease burden are suboptimal. Daratumumab is a monoclonal antibody that targets CD38, an antigen expressed on nearly all myeloma cells. Purpose To demonstrate preclinical and first-in-human application of an antibody composed of the native daratumumab labeled with the positron-emitting radionuclide zirconium 89 (
Indexed as
ADP-ribosyl Cyclase 1Disease Models, AnimalMembrane GlycoproteinsAnimalsAntibodies, MonoclonalBone NeoplasmsDeferoxamineHeterograftsHumansMultiple MyelomaPositron Emission Tomography Computed TomographyProspective StudiesSensitivity and SpecificityTumor BurdenZirconiumADP-ribosyl Cyclase 1Antibodies, MonoclonalCD38 protein, humanCd38 protein, mousedaratumumabDeferoxamineMembrane GlycoproteinsZirconium
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.